Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of January 2022. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions.
| Transaction Date | Instrument | Price per Share | Volume | Transaction Type |
|---|---|---|---|---|
| 2022-01-14 | Ordinary Shares (25p each) | £16.3853 | 26 | Acquisition (Dividend Re-investment) |
| 2022-01-14 | Ordinary Shares (25p each) | £16.3853 | 22 | Acquisition (Dividend Re-investment) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine acquisitions of shares by executives following the re-investment of dividends paid on January 13, 2022.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of insider trading activity compliant with regulatory requirements.
Key Facts for Investor Verification
- Executives Involved: Mr. D Redfern (Chief Strategy Officer) and Ms. V Whyte (Company Secretary).
- Transaction Nature: Both transactions were acquisitions of ordinary shares via dividend re-investment plans (DRIP) within Individual Savings Accounts (ISAs).
- Market Data: Shares were acquired on the London Stock Exchange (XLON) at a price of £16.3853 per share.
- Dividend Context: The transactions relate to dividends paid to shareholders on January 13, 2022.